Mechanism of action of the SPARI vilazodone: Serotonin 1A partial agonist and reuptake inhibitor

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 105-109

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VILAZODONE; 6 HYDROXYBUSPIRONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; PLACEBO; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; COMPARATIVE EFFECTIVENESS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; NERVE CONDUCTION; PRIORITY JOURNAL; UNITED STATES; HUMAN; NONHUMAN; PARTIAL AGONISM; SEXUAL DYSFUNCTION; ANIMAL; DEPRESSION; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSION; HUMANS; INDOLES; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84901704975     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000169     Document Type: Article

References (9)

1. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.
2. Bartoszky GD, Hegenbart R, Zielger H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5HT1A receptor agonistic properties. Eur J Pharmacol. 1997; 322(2-3): 147-153. (Pubitemid 27122887)
3. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5HT1A receptor partial agonist/ serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005; 510(1-2): 49-57. (Pubitemid 40312389)
4. Page ME, Cryan JF, Sullivan A, et al. Behavioral and neurochemical effects of 5-(4-(4-(5-cyano-3-indolyl)- butyl)-butyl)-1-piperazinyl)benzofuran- 2-carboxamine (EMD 68843): A combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine 1A receptor partial agonist. J Pharmacol Exp Ther. 2002; 302(3): 1220-1227. (Pubitemid 34920246)
5. Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013; 18(3): 113-117.
6. Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and (carbonyl-(11)C)WAY-100635. Nucl Med Biol. 2000; 27(5): 509-513. (Pubitemid 30658155)
7. Rickels K, Athanasious M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(3): 326-333.
8. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72(4): 441-447.
9. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: A brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011; 1(3): 81-87.